TURBT术后吡柔比星膀胱灌注预防肿瘤复发的疗效分析

Intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of bladder cancer

关键词:  膀胱肿瘤  吡柔比星  TURBT  膀胱灌注

Key words:  bladder cancer  pirarubicin  TURBT  intravesical instillation

摘要:

［目的］评价吡柔比星（THP）膀胱灌注预防膀胱肿瘤TURBT术后复发的疗效和安全性。［方法］1999年11月~2003年10月，膀胱肿瘤TURBT术后患者63例，术后接受THP30 mg膀胱灌注治疗，随访12~53个月。［结果］膀胱癌TURBT术后THP膀胱灌注，术后1年未复发率89.8%，术后2年未复发率83.1%，术后3年未复发率76.3%；膀胱灌注THP副反应发生率为28.57%。［结论］应用THP30 mg/50 mL(600 μg/mL)，TURBT术后尽早膀胱灌注，膀胱内保留30 min，采用为期1年的短期疗程，对于预防膀胱肿瘤TURBT术后复发有较好的疗效。

Abstract:

［Objective］To evaluate the effectiveness and safety of intravesical instillation of THP after transurethral resection of bladder cancer (TURBT).［Methods］From Nov. 1999 to Oct. 2003, a total of 63 patients were treated with intravesical instillation of THP after TURBT, the patients were followed up by cystscopy for 12~53 months.［Results］The non-recurrence rates at 1, 2 and 3 years were 89.8%, 83.1% and 76.3%, respectively. The side effect rate was 28.57%.［Conclusion］Our findings demonstrated that short-term (1 year), 30 minutes instillation intensive intravesical instillation of THP 30 mg/50 mL (600 μg/mL) after TURBT was a safe and effective therapy.